OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Journal is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Epidemiology of Triple-Negative Breast Cancer	155
Immunotherapy in Triple-Negative Breast Cancer	42
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy	37
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?	34
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease	34
Cytokine Release Syndrome Biology and Management	31
PARP Inhibitors in Pancreatic Cancer	23
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer	21
Challenges and Errors in Genetic Testing	16
Triple-Negative Breast Cancer	15
Obesity and Energy Balance Considerations in Triple-Negative Breast Cancer	14
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors	14
Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer	13
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	13
Immunotherapy Use in Patients With Lung Cancer and Comorbidities	13
DNA Damage Repair Inhibitors—Combination Therapies	12
Fecal Microbiota Transplantation as a Cancer Therapeutic	11
Mechanistic Effects of Estrogens on Breast Cancer	11
DNA Damage Response in Glioblastoma	11
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	10
Hormone Replacement Therapy After Breast Cancer	10
Clinical Targeting of Altered Metabolism in High-Grade Glioma	10
Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?	9
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations	9
Lessons for Oncology From the COVID-19 Pandemic	9

Targeted Treatment of Triple-Negative Breast Cancer	9
Neoantigen-Specific T Cells in Adoptive Cell Therapy	9
The Menopause Management Vacuum	8
Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy	8
Neurotoxicity Biology and Management	7
The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment	7
Current State of Cell Therapies for Breast Cancer	7
Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?	7
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	7
Stereotactic Body Radiotherapy in Oligomestatic/Oligoprogressive Sarcoma	7
Epidemiology and Pathogenesis of Myelodysplastic Syndrome	7
Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?	7
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	7
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	7
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2	6
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer	6
Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute–Designated Cancer Centers	6
Estrogen for the Treatment and Prevention of Breast Cancer	6
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	6
Circulating Biomarkers in Glioblastoma	6
COVID-19 and Chronic Lymphocytic Leukemia	6
The Gut Microbiome and Pancreatic Cancer Development and Treatment	6
STING Agonists in Head and Neck Squamous Cell Carcinoma	6
Current State of Cell Therapies for Genitourinary Malignancies	6
Moving Immunotherapy Into Early-Stage Lung Cancer	6
Menopausal Hormone Therapy and Breast Cancer	6
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia	6
Overview of Lung Cancer Immunotherapy	6
Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma	6
Telemedicine Across the Cancer Care Continuum	6
Minimal Residual Disease in Multiple Myeloma	6
What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?	5
The Evolving Molecular Landscape of High-Grade Gliomas	5
Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia	5
Integrating New Therapies for Chronic Lymphocytic Leukemia	5
Off-the-Shelf Chimeric Antigen Receptor T Cells	5
Gene Expression Profiles in Cancers and Their Therapeutic Implications	5
Toxicities From Antibody-Drug Conjugates	5
Toward the Next Generation of High-Grade Glioma Clinical Trials in the Era of Precision Medicine	5
The Biology of Chronic Lymphocytic Leukemia	5
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	5
Autoimmune Cytopenia in CLL	5